Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.

European urology - 1 Nov 2006

Burger Maximilian, Denzinger Stefan, Hammerschmied Christine, Tannapfel Andrea, Maderstorfer Armin, Wieland Wolf Ferdinand, Hartmann Arndt, Stoehr Robert

Abstract excerpt

OBJECTIVES: A dysregulated mitogen-activated protein kinase (MAPK) pathway plays an important role in various malignancies and is often mediated by mutations in several oncogenes (eg, RAF, RAS). B-RAF mutations, predominantly the specific V600E mutation and additional alterations in exons 11 and 15, were frequently detected in malignant melanomas, papillary thyroid tumors, and colorectal cancers with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glutamine

Share to Microsatellite Instability

Share to Mitogen-Activated Protein Kinases

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Valine

Source

Identifiers

PMID: 16413100
DOI: 10.1016/j.eururo.2005.11.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.PMID 16413100Read ↗

BRAF and KRAS mutations in prostatic adenocarcinoma.Semantic proximity Read ↗

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.Semantic proximity Read ↗

Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases.Semantic proximity Read ↗

Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations.Semantic proximity Read ↗

Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancerSemantic proximity Read ↗

MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.Semantic proximity Read ↗

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.Semantic proximity Read ↗

Mutations of <i>BRAF</i> and <i>RAS</i> are rare events in germ cell tumoursSemantic proximity Read ↗

KRAS and BRAF mutations in prostate carcinomas of Chinese patients.Semantic proximity Read ↗

No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.Semantic proximity Read ↗

Constitutive Activation of the Mitogen-Activated Protein Kinase Signaling Pathway in Acral MelanomasSemantic proximity Read ↗

Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.